Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113132170> ?p ?o ?g. }
- W3113132170 abstract "Background Oral anticoagulants may improve the survival of people with cancer through both an antitumor effect and antithrombotic effect, yet increase the risk of bleeding. Objectives To evaluate the efficacy and safety of oral anticoagulants in ambulatory people with cancer undergoing chemotherapy, hormonal therapy, immunotherapy or radiotherapy, but otherwise have no standard therapeutic or prophylactic indication for anticoagulation. Search methods We conducted a comprehensive literature search in February 2016 that included a major electronic search of Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 1), MEDLINE (Ovid) and Embase (Ovid); handsearching of conference proceedings; checking of references of included studies; a search for ongoing studies; and using the 'related citation' feature in PubMed. As part of the living systematic review approach, we are running continual searches and will incorporate new evidence rapidly after it is identified. This update of the systematic review is based on the findings of a literature search conducted on 14 December 2017. Selection criteria Randomized controlled trials (RCTs) assessing the benefits and harms of vitamin K antagonist (VKA) or direct oral anticoagulants (DOAC) in ambulatory people with cancer. These participants are typically undergoing systemic anticancer therapy, possibly including chemotherapy, target therapy, immunotherapy or radiotherapy, but otherwise have no standard therapeutic or prophylactic indication for anticoagulation. Data collection and analysis Using a standardized form, we extracted data in duplicate on study design, participants, intervention outcomes of interest and risk of bias. Outcomes of interest included all‐cause mortality, symptomatic venous thromboembolism (VTE), symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), major bleeding, minor bleeding and health‐related quality of life (HRQoL). We assessed the certainty of evidence for each outcome using the GRADE approach (GRADE Handbook). Main results Of 8545 identified citations, including 7668 unique citations, 16 papers reporting on 7 RCTs fulfilled the inclusion criteria. These trials enrolled 1486 participants. The oral anticoagulant was warfarin in six of these RCTs and apixaban in the seventh RCT. The comparator was either placebo or no intervention. The meta‐analysis of the studies comparing VKA to no VKA did not rule out a clinically significant increase or decrease in mortality at one year (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.87 to 1.03; risk difference (RD) 29 fewer per 1000, 95% CI 75 fewer to 17 more; moderate certainty evidence). One study assessed the effect of VKA on thrombotic outcomes. The study did not rule out a clinically significant increase or decrease in PE when comparing VKA to no VKA (RR 1.05, 95% CI 0.07 to 16.58; RD 0 fewer per 1000, 95% CI 6 fewer to 98 more; very low certainty evidence), but found that VKA compared to no VKA likely decreases the incidence of DVT (RR 0.08, 95% CI 0.00 to 1.42; RD 35 fewer per 1000, 95% CI 38 fewer to 16 more; low certainty evidence). VKA increased both major bleeding (RR 2.93, 95% CI 1.86 to 4.62; RD 107 more per 1000, 95% CI 48 more to 201 more; moderate certainty evidence) and minor bleeding (RR 3.14, 95% CI 1.85 to 5.32; RD 167 more per 1000, 95% CI 66 more to 337 more; moderate certainty evidence). The study assessing the effect of DOAC compared to no DOAC did not rule out a clinically significant increase or decrease in mortality at three months (RR 0.24, 95% CI 0.02 to 2.56; RD 51 fewer per 1000, 95% CI 65 fewer to 104 more; low certainty evidence), PE (RR 0.16, 95% CI 0.01 to 3.91; RD 28 fewer per 1000, 95% CI 33 fewer to 97 more; low certainty evidence), symptomatic DVT (RR 0.07, 95% CI 0.00 to 1.32; RD 93 fewer per 1000, 95% CI 100 fewer to 32 more; low certainty evidence), major bleeding (RR 0.16, 95% CI 0.01 to 3.91; RD 28 fewer per 1000, 95% CI 33 fewer to 97 more; low certainty evidence); and minor bleeding (RR 4.43, 95% CI 0.25 to 79.68; RD 0 fewer per 1000, 95% CI 0 fewer to 8 more; low certainty evidence). Authors' conclusions The existing evidence does not show a mortality benefit from oral anticoagulation in people with cancer but suggests an increased risk for bleeding. Editorial note: this is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence, as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review." @default.
- W3113132170 created "2020-12-21" @default.
- W3113132170 creator A5013491140 @default.
- W3113132170 creator A5024459640 @default.
- W3113132170 creator A5026324699 @default.
- W3113132170 creator A5041615321 @default.
- W3113132170 creator A5065403219 @default.
- W3113132170 creator A5071868716 @default.
- W3113132170 creator A5082149678 @default.
- W3113132170 creator A5084919462 @default.
- W3113132170 creator A5087847130 @default.
- W3113132170 creator A5090182271 @default.
- W3113132170 date "2017-12-29" @default.
- W3113132170 modified "2023-09-24" @default.
- W3113132170 title "Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation" @default.
- W3113132170 cites W1516783539 @default.
- W3113132170 cites W1531238400 @default.
- W3113132170 cites W1542673764 @default.
- W3113132170 cites W1634950970 @default.
- W3113132170 cites W167323299 @default.
- W3113132170 cites W1821404797 @default.
- W3113132170 cites W1835668326 @default.
- W3113132170 cites W1847026520 @default.
- W3113132170 cites W1863488026 @default.
- W3113132170 cites W1895600627 @default.
- W3113132170 cites W1963654054 @default.
- W3113132170 cites W1968399105 @default.
- W3113132170 cites W1972167184 @default.
- W3113132170 cites W1972875444 @default.
- W3113132170 cites W1977149417 @default.
- W3113132170 cites W1979267823 @default.
- W3113132170 cites W1980358129 @default.
- W3113132170 cites W1981259575 @default.
- W3113132170 cites W1989844406 @default.
- W3113132170 cites W1990154448 @default.
- W3113132170 cites W1991658274 @default.
- W3113132170 cites W1992661527 @default.
- W3113132170 cites W1995391277 @default.
- W3113132170 cites W2000287607 @default.
- W3113132170 cites W2002698748 @default.
- W3113132170 cites W2002938738 @default.
- W3113132170 cites W2003505590 @default.
- W3113132170 cites W2012424656 @default.
- W3113132170 cites W2012778426 @default.
- W3113132170 cites W2012934272 @default.
- W3113132170 cites W2013945874 @default.
- W3113132170 cites W2014412826 @default.
- W3113132170 cites W2019336592 @default.
- W3113132170 cites W2026895719 @default.
- W3113132170 cites W2028608222 @default.
- W3113132170 cites W2030512823 @default.
- W3113132170 cites W2040586160 @default.
- W3113132170 cites W2040800118 @default.
- W3113132170 cites W2048025180 @default.
- W3113132170 cites W2048778787 @default.
- W3113132170 cites W2051073735 @default.
- W3113132170 cites W2052540488 @default.
- W3113132170 cites W2052685518 @default.
- W3113132170 cites W2054724286 @default.
- W3113132170 cites W2058169671 @default.
- W3113132170 cites W2061227527 @default.
- W3113132170 cites W2064955438 @default.
- W3113132170 cites W2065378584 @default.
- W3113132170 cites W2068476516 @default.
- W3113132170 cites W2071682406 @default.
- W3113132170 cites W2076903503 @default.
- W3113132170 cites W2083637906 @default.
- W3113132170 cites W2083815143 @default.
- W3113132170 cites W2085354161 @default.
- W3113132170 cites W2085728164 @default.
- W3113132170 cites W2093822964 @default.
- W3113132170 cites W2094783832 @default.
- W3113132170 cites W2100184560 @default.
- W3113132170 cites W2102163277 @default.
- W3113132170 cites W2102537088 @default.
- W3113132170 cites W2103419160 @default.
- W3113132170 cites W2103969621 @default.
- W3113132170 cites W2107328434 @default.
- W3113132170 cites W2109042377 @default.
- W3113132170 cites W2112378432 @default.
- W3113132170 cites W2112878705 @default.
- W3113132170 cites W2113020324 @default.
- W3113132170 cites W2120130633 @default.
- W3113132170 cites W2124101267 @default.
- W3113132170 cites W2125435699 @default.
- W3113132170 cites W2127185770 @default.
- W3113132170 cites W2132381095 @default.
- W3113132170 cites W2134683286 @default.
- W3113132170 cites W2135918458 @default.
- W3113132170 cites W2135936995 @default.
- W3113132170 cites W2137283681 @default.
- W3113132170 cites W2140155526 @default.
- W3113132170 cites W2141713306 @default.
- W3113132170 cites W2150605046 @default.
- W3113132170 cites W2154738014 @default.
- W3113132170 cites W2158961472 @default.
- W3113132170 cites W2169333669 @default.
- W3113132170 cites W2196970594 @default.
- W3113132170 cites W2212466758 @default.
- W3113132170 cites W2227501530 @default.